Sequent Scientific Limited (SEQUENT.BO)
INR 181.65
(-0.6%)
INR 181.65
(-0.6%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.97 Billion INR | -42.69% |
| 2022 | 5.19 Billion INR | -8.13% |
| 2021 | 5.65 Billion INR | -8.08% |
| 2020 | 6.15 Billion INR | 17.88% |
| 2019 | 5.22 Billion INR | 16.74% |
| 2018 | 4.47 Billion INR | 24.62% |
| 2017 | 3.58 Billion INR | 19.13% |
| 2016 | 3.01 Billion INR | 14.43% |
| 2015 | 2.63 Billion INR | 45.0% |
| 2014 | 1.81 Billion INR | 21.56% |
| 2013 | 1.49 Billion INR | 30.97% |
| 2012 | 1.14 Billion INR | -12.77% |
| 2011 | 1.3 Billion INR | -5.38% |
| 2010 | 1.38 Billion INR | -11.88% |
| 2009 | 1.56 Billion INR | 102.39% |
| 2008 | 774.76 Million INR | 282.82% |
| 2007 | 202.38 Million INR | 40.97% |
| 2006 | 143.56 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 976.2 Million INR | 10.95% |
| 2023 FY | 2.97 Billion INR | -42.69% |
| 2023 Q1 | 1.38 Billion INR | 78.48% |
| 2023 Q2 | 1.56 Billion INR | 12.86% |
| 2023 Q3 | 1.48 Billion INR | -4.78% |
| 2023 Q4 | 879.86 Million INR | -40.84% |
| 2022 Q2 | 1.39 Billion INR | -3.39% |
| 2022 Q3 | 1.57 Billion INR | 13.0% |
| 2022 FY | 5.19 Billion INR | -8.13% |
| 2022 Q4 | 775.43 Million INR | -50.89% |
| 2022 Q1 | 1.44 Billion INR | 30.48% |
| 2021 Q4 | 1.1 Billion INR | -26.37% |
| 2021 Q2 | 1.5 Billion INR | -2.65% |
| 2021 FY | 5.65 Billion INR | -8.08% |
| 2021 Q3 | 1.5 Billion INR | 0.26% |
| 2021 Q1 | 1.54 Billion INR | 29.3% |
| 2020 FY | 6.15 Billion INR | 17.88% |
| 2020 Q4 | 1.19 Billion INR | -32.95% |
| 2020 Q3 | 1.77 Billion INR | 5.9% |
| 2020 Q2 | 1.67 Billion INR | 15.85% |
| 2020 Q1 | 1.44 Billion INR | 46.34% |
| 2019 Q3 | 1.54 Billion INR | 15.88% |
| 2019 Q2 | 1.33 Billion INR | -1.07% |
| 2019 Q1 | 1.34 Billion INR | 54.15% |
| 2019 Q4 | 990.81 Million INR | -35.93% |
| 2019 FY | 5.22 Billion INR | 16.74% |
| 2018 Q1 | 1.08 Billion INR | 30.01% |
| 2018 Q4 | 875.16 Million INR | -32.3% |
| 2018 Q3 | 1.29 Billion INR | 7.14% |
| 2018 Q2 | 1.2 Billion INR | 11.06% |
| 2018 FY | 4.47 Billion INR | 24.62% |
| 2017 Q2 | 847.5 Million INR | -2.06% |
| 2017 FY | 3.58 Billion INR | 19.13% |
| 2017 Q1 | 865.35 Million INR | -51.49% |
| 2017 Q3 | 1.04 Billion INR | 23.64% |
| 2017 Q4 | 835.62 Million INR | -20.25% |
| 2016 Q4 | 1.78 Billion INR | 85.38% |
| 2016 Q2 | 1.12 Billion INR | 28.98% |
| 2016 FY | 3.01 Billion INR | 14.43% |
| 2016 Q1 | 871.55 Million INR | 63.3% |
| 2016 Q3 | 962.22 Million INR | -14.41% |
| 2015 Q1 | 678.88 Million INR | 118.26% |
| 2015 FY | 2.63 Billion INR | 45.0% |
| 2015 Q4 | 533.71 Million INR | -28.25% |
| 2015 Q3 | 743.85 Million INR | -7.73% |
| 2015 Q2 | 806.13 Million INR | 18.74% |
| 2014 FY | 1.81 Billion INR | 21.56% |
| 2014 Q4 | 311.05 Million INR | -43.38% |
| 2014 Q3 | 549.41 Million INR | 24.04% |
| 2014 Q2 | 442.93 Million INR | -5.61% |
| 2014 Q1 | 469.27 Million INR | 769.2% |
| 2013 Q3 | 518.52 Million INR | -10.56% |
| 2013 Q1 | 522 Million INR | 333.2% |
| 2013 Q4 | 53.99 Million INR | -89.59% |
| 2013 FY | 1.49 Billion INR | 30.97% |
| 2013 Q2 | 579.73 Million INR | 11.06% |
| 2012 Q2 | 300.51 Million INR | -8.31% |
| 2012 FY | 1.14 Billion INR | -12.77% |
| 2012 Q1 | 327.74 Million INR | 0.0% |
| 2012 Q3 | 391.59 Million INR | 30.31% |
| 2012 Q4 | 120.5 Million INR | -69.23% |
| 2011 FY | 1.3 Billion INR | -5.38% |
| 2010 FY | 1.38 Billion INR | -11.88% |
| 2009 FY | 1.56 Billion INR | 102.39% |
| 2008 FY | 774.76 Million INR | 282.82% |
| 2007 FY | 202.38 Million INR | 40.97% |
| 2006 FY | 143.56 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Ajanta Pharma Limited | 21.06 Billion INR | 85.859% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | -91.37% |
| Sigachi Industries Limited | 2 Billion INR | -48.767% |
| Bal Pharma Limited | 770.19 Million INR | -286.75% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 51.912% |
| Medico Remedies Limited | 262.14 Million INR | -1036.295% |
| Lasa Supergenerics Limited | 121.02 Million INR | -2361.15% |
| Venus Remedies Limited | 2.18 Billion INR | -36.477% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 594.472% |
| Alpa Laboratories Limited | 188.89 Million INR | -1476.924% |
| Nectar Lifesciences Limited | 2.97 Billion INR | -0.224% |
| Shilpa Medicare Limited | 3.54 Billion INR | 16.018% |
| Aarti Drugs Limited | 8.31 Billion INR | 64.182% |
| Lupin Limited | 123.71 Billion INR | 97.592% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 98.074% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 97.621% |
| Windlas Biotech Limited | 1.33 Billion INR | -122.493% |
| Suven Life Sciences Limited | -200.79 Million INR | 1583.453% |
| Eris Lifesciences Limited | 10.42 Billion INR | 71.432% |
| Valiant Laboratories Limited | -60.66 Million INR | 5010.21% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 86.878% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -245.881% |
| Ipca Laboratories Limited | 29.8 Billion INR | 90.008% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 19.394% |
| Achyut Healthcare Limited | 4.86 Million INR | -61178.132% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 98.848% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -102.386% |
| RPG Life Sciences Limited | 2.48 Billion INR | -19.965% |
| Mankind Pharma Limited | 44.52 Billion INR | 93.309% |
| Laurus Labs Limited | 24.62 Billion INR | 87.901% |
| Piramal Pharma Limited | 24.47 Billion INR | 87.827% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -216.079% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 93.629% |
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 88.877% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 95.704% |
| Unichem Laboratories Limited | 4.86 Billion INR | 38.771% |
| Novartis India Limited | 1.32 Billion INR | -124.488% |
| Wanbury Limited | 1.73 Billion INR | -72.117% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 27.758% |
| Wockhardt Limited | 16.24 Billion INR | 81.658% |
| Themis Medicare Limited | 1.5 Billion INR | -98.066% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -356.447% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 84.836% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 76.042% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 98.179% |
| Divi's Laboratories Limited | 32.44 Billion INR | 90.818% |
| NATCO Pharma Limited | 25.73 Billion INR | 88.426% |
| Gufic Biosciences Limited | 4.16 Billion INR | 28.528% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 34.974% |
| Ind-Swift Limited | 2.17 Billion INR | -37.109% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 48.477% |
| FDC Limited | 8.33 Billion INR | 64.261% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -1445.57% |
| Granules India Limited | 16.79 Billion INR | 82.269% |
| Medicamen Biotech Limited | 495.49 Million INR | -501.162% |
| Alkem Laboratories Limited | 52.29 Billion INR | 94.304% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 52.131% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -20330.667% |
| Brooks Laboratories Limited | 65.62 Million INR | -4439.363% |
| Megasoft Limited | 342.07 Million INR | -770.793% |
| ZIM Laboratories Limited | 1.26 Billion INR | -135.122% |
| Strides Pharma Science Limited | 14.38 Billion INR | 79.297% |
| Neuland Laboratories Limited | 8.24 Billion INR | 63.885% |
| Morepen Laboratories Limited | 6.16 Billion INR | 51.654% |
| Hikal Limited | 3.14 Billion INR | 5.229% |
| Indoco Remedies Limited | 6.04 Billion INR | 50.694% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 48.919% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -380.071% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -323.353% |
| Hester Biosciences Limited | 1.27 Billion INR | -133.874% |